XOMA Initiates Phase 3 Gevokizumab Trial in Patients With Non-Infectious Uveitis and Phase 2 Gevokizumab Trial in Patients With Erosive Osteoarthritis Jun 27, 2012 8:00am EDT
XOMA Reports Financial Results for First Quarter 2012 and Highlights Recent Achievements May 08, 2012 4:05pm EDT
XOMA to Announce First Quarter 2012 Financial Results and Host Webcast on May 8 May 01, 2012 9:00am EDT
Photo Release -- XOMA Integrates Research, Preclinical and Clinical Development Under the Leadership of Paul Rubin, MD Apr 24, 2012 4:30pm EDT
Study Establishes XOMA's XMetA as the First Allosteric Insulin Receptor-Activating Antibody to Improve Glycemic Control In Vivo Mar 08, 2012 8:01am EST
XOMA to Announce Fourth Quarter and Year-End 2011 Financial Results and Host Webcast Conference Call on March 14 Mar 07, 2012 4:05pm EST
XOMA Announces Pricing of $39.2 Million Public Offering of Common Stock and Warrants Mar 06, 2012 9:00am EST
